5 benefits that 3D cell culture will bring to pharmaceutical drug development
Advances in 3D cell culture excite us — that’s why we got into this game. But what does it mean for the future of your healthcare?
Lucero unveils new brand
Lucero unveils rebrand as they enter next stage of development.
Lucero awarded €1.3M Transition Grant by European Innovation Council
Lucero will ring in the new year with generous funding from the European Innovation Council (EIC) to continue the development of our 3D cell culture handling platform.
Lucero awarded Vinnova Innovative Startups Stage 2 grant
Lucero awarded 900 000 SEK Vinnova Innovative Startups Stage 2 grant to build on Stage 1 progress in preparation for an on-site pharmaceutical pilot project and Seed round funding.
Tech Update: Promising local heating data during and post-irradiation using optical tweezers
Preliminary data showed a temperature increase of less than 1 degree C in HepG2 cells during exposure to optical tweezers.
Lucero granted international project to advance microfluidic technology
Lucero has been granted a project by the European initiative, MedPhab, to accelerate the development of its novel microfluidic well plates with the help of partners, Joanneum Research and The Technical Research Center of Finland (VTT).
Lucero moves to AstraZeneca’s BioVentureHub
Lucero has moved its offices to AstraZeneca’s BioVentureHub in Mölndal, Sweden.
Tinde Höjer joins Lucero team
Tinde Höjer joins the Lucero team to focus on microfluidic development and 3D cell culture handling.
Tech Update: Identifying miniature liver spheroids using Lucero AI
We are happy to share our latest results on spheroid detection and classification using our convolutional neural network that was trained with images of spheroids taken on our very own prototype!
Lucero joins Nanoscale Drug Testing consortium
The consortium aims to develop a “near-patient drug development” strategy that includes using 3D cell models comprised of patient-derived cells. The strategy will reduce clinical failures, enable the development of more effective treatments at a lower cost, and allow the right drug leads to be matched with the right patient subgroup.